119th Congress · introduced in the Senate · May 15, 2025
MAPS Act
Official title from Congress.gov
Latest action (Mar 19, 2026): Committee on Health, Education, Labor, and Pensions. Hearings held.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in Senate (May 15, 2025)
Mapping America’s Pharmaceutical Supply Act or the MAPS Act
This bill requires the Food and Drug Administration (FDA) to continually update its essential medicines list and identify risks and vulnerabilities in the associated supply chains.
In 2020, in response to an executive order, the FDA published a list of essential medicines deemed medically necessary to have available at all times. The bill requires the FDA to update and maintain this list to include drugs and ingredients (1) related to responding to public health threats and emergency incidents, (2) of greatest priority for providing health care and at high risk of shortage, (3) the shortage of which would adversely affect patients with chronic conditions, and (4) that the Department of Defense (DOD) determines to be critical for military preparedness. The FDA must update the list at least every two years.
Also, the bill requires the FDA to conduct a risk assessment of the supply chains for drugs and ingredients on the list and annually report its findings to Congress. The assessment must include information about key manufacturing materials, drugs with primarily foreign suppliers, manufacturing capacity, relevant public health and national security risks, and risk mitigation strategies.
Additionally, the Department of Health and Human Services, in coordination with other agencies, must map and monitor relevant supply chains to identify vulnerabilities and provide an annual status report to Congress.
Finally, DOD must report to Congress every 180 days on the drugs DOD purchased that were manufactured in or sourced from China.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Committee on Health, Education, Labor, and Pensions. Hearings held.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Actions from Congress.gov, newest first.
Computer security and identity theft · Congressional oversight · Data collection, sharing, protection · Government information and archives · Manufacturing · Prescription drugs · Strategic materials and reserves · Supply chain
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
51 citations; showing the 25 most recently posted.
THE UNITED STATES PHARMACOPEIAL CONVENTION · lobbying firm or registrant: THE UNITED STATES PHARMACOPEIAL CONVENTION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$120,000
Spent on own lobbying
S. 1784, H.R. 4191 - Mapping America's Pharmaceutical Supply (MAPS) Act: Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consum…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VIZIENT INC · lobbying firm or registrant: VIZIENT, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$300,000
Spent on own lobbying
…ng Seniors' Timely Access to Care Act (H.R. 3514/S.1816). Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191). Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) . Continued monitoring and encouraged passage o…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$390,000
Spent on own lobbying
…ical supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health a…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Manufacturing
$390,000
Spent on own lobbying
…ical supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health a…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 18, 2026 · issue area: Budget/Appropriations
$90,000
Paid to lobbying firm
…ed Appropriations Act, 2026 (PL 119-75); Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR ACCESSIBLE MEDICINES · lobbying firm or registrant: ASSOCIATION FOR ACCESSIBLE MEDICINES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 17, 2026 · issue area: Pharmacy
$770,000
Spent on own lobbying
…Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to B…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$80,000
Spent on own lobbying
…air and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply cha…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE UNITED STATES PHARMACOPEIAL CONVENTION · lobbying firm or registrant: THE UNITED STATES PHARMACOPEIAL CONVENTION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · amended · posted Jul 20, 2026 · issue area: Health Issues
$130,000
Spent on own lobbying
S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consum…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE UNITED STATES PHARMACOPEIAL CONVENTION · lobbying firm or registrant: THE UNITED STATES PHARMACOPEIAL CONVENTION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$120,000
Spent on own lobbying
S. 1784, H.R. 4191 - Mapping America's Pharmaceutical Supply (MAPS) Act - Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consu…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VIZIENT INC · lobbying firm or registrant: VIZIENT, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$320,000
Spent on own lobbying
…ing Seniors' Timely Access to Care Act (H.R. 3514/S.1816) Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Continued monitoring and encouraged passage of t…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$370,000
Spent on own lobbying
…d to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health a…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Manufacturing
$370,000
Spent on own lobbying
…d to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health a…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 18, 2026 · issue area: Budget/Appropriations
$90,000
Paid to lobbying firm
…ppropriations Act, 2026 (PL 119-75); Issues related to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Health Issues
$480,000
Spent on own lobbying
…air and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply cha…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VIZIENT INC · lobbying firm or registrant: VIZIENT, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$320,000
Spent on own lobbying
…ssage of the Biosimilar Red Tape Elimination Act (S.1954) Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Continued monitoring and encouraged passage of t…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Budget/Appropriations
$90,000
Paid to lobbying firm
…ed Appropriations Act, 2026 (PL 119-75); Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$400,000
Spent on own lobbying
…d to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health a…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Manufacturing
$400,000
Spent on own lobbying
…d to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health a…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AARP · lobbying firm or registrant: AARP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Pharmacy
$3,830,000
Spent on own lobbying
…Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act. S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act. S. 1784/H.R. 4191, the Mapping America's Pharmaceutical Supply Act or the MAPS Act. No bill number. Lifetime prescription drug price increases. No bill number. Discuss…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · lobbying firm or registrant: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$240,000
Spent on own lobbying
…o drug pricing, drug shortages, drug importation plans, and the drug supply chain, including support for the Mapping Americas Pharmaceutical Supply (MAPS) Act (S. 1784/S. Amdt. 3753). Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharma…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TURBARE MANUFACTURING · lobbying firm or registrant: NATURAL STATE CONSULTING AND STRATEGIES
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 16, 2026 · issue area: Pharmacy
$20,000
Paid to lobbying firm
Lobbied in favor of reform to country of origin packaging on pharmaceutical drugs. S. 1891 PILLS Act S.1784 MAPS Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 15, 2026 · issue area: Health Issues
$210,000
Spent on own lobbying
…Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply cha…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VIZIENT INC · lobbying firm or registrant: VIZIENT, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Health Issues
$320,000
Spent on own lobbying
…ased notification by manufacturers for a surges in demand Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Continued monitoring and encouraged passage of the Biosimilar Red Tape Elimination Act (S.1954) Continued monitoring and encouraged passage of the Re…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Copyright/Patent/Trademark
$810,000
Spent on own lobbying
…. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 1784 MAPS Act S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN HOSPITAL ASSOCIATION · lobbying firm or registrant: AMERICAN HOSPITAL ASSOCIATION
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$6,570,000
Spent on own lobbying
…/ S. 709, Conrad State 30 and Physician Access Reauthorization Act, all provisions; S. 1874, Title VIII Nursing Workforce Reauthorization Act, all provisions; S. 1784 / H.R. 4191, The Mapping America's Pharmaceutical Supply (MAPS) Act, all provisions; H.R. 5283 / S. 2759, Healthcare Workforce Resilience Act, all provisions;…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing